Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tobemstomig · 3 trials · 3 indications
ORR is defined as the percentage of participants who experience a complete reponse or partial response on two consecutive occasions at least 4 weeks apart as determined by the investigator according to RECIST v1.1.
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | Participants will receive tobemstomig every 3 weeks, plus nab-paclitaxel administered on a repeating schedule of 3 weeks on, 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner. |
| Arm B | ACTIVE_COMPARATOR | Participants will receive pembrolizumab every 3 weeks, plus nab-paclitaxel administered on a repeating schedule of 3 weeks on, 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner. |
| Arm A (Tobemstomig + Axitinib) | EXPERIMENTAL | Participants will receive intravenous (IV) tobemstomig every three weeks (Q3W) on Day 1 of each 21-day cycle. Participants will also receive oral (PO) axitinib twice daily (BID). |
| Arm B (Tobemstomig + Tiragolumab + Axitinib) | EXPERIMENTAL | Participants will receive IV tobemstomig followed by IV tiragolumab Q3W on Day 1 of 21-day cycle. Participants will also receive axitinib PO BID. |
| Control Arm (Pembrolizumab + Axitinib) | ACTIVE_COMPARATOR | Participants will receive IV pembrolizumab Q3W on Day 1 of each 21-day cycle. Participants will also receive axitinib PO BID. |
| Arm A: Tobemstomig + Platinum-Based Chemotherapy | EXPERIMENTAL | Participants with non-squamous (NSQ) NSCLC will receive induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin, all on Day 1 every 3 weeks (Q3W) for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig together with pemetrexed until disease progression or treatment discontinuation. Participants with squamous (SQ) NSCLC will receive blinded tobemstomig in combination with paclitaxel and carboplatin, all on Day 1 Q3W for four 21 day cycles, followed by blinded tobemstomig (on Day 1) Q3W until disease progression or treatment discontinuation. |
| Arm B: Pembrolizumab + Platinum-Based Chemotherapy | ACTIVE_COMPARATOR | Participants with NSQ NSCLC will receive induction treatment with blinded pembrolizumab in combination with pemetrexed and carboplatin, all on Day 1 Q3W for four 21-day cycles, followed by a maintenance therapy with blinded pembrolizumab together with pemetrexed Q3W until disease progression or treatment discontinuation. Participants with SQ NSCLC will receive blinded pembrolizumab in combination with paclitaxel and carboplatin, all on Day 1 Q3W for four 21-day cycles, followed by blinded pembrolizumab (on Day 1) Q3W until disease progression or treatment discontinuation. |
| Name | Type | Description |
|---|---|---|
| Tobemstomig | DRUG | Participants will receive intravenous (IV) tobemstomig every 3 weeks (Q3W) until disease progression or until up to 24 months after the first treatment, whichever is sooner. |
| Pembrolizumab | DRUG | Participants will receive IV pembrolizumab Q3W until disease progression or until up to 24 months after the first treatment, whichever is sooner. |
| Nab-Paclitaxel | DRUG | Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner. |
| Tiragolumab | DRUG | Participants will receive IV tiragolumab Q3W. |
| Axitinib | DRUG | Participants will receive axitinib PO BID. |
| Paclitaxel | DRUG | Participants will receive IV paclitaxel Q3W for four 21-day cycles |
| Pemetrexed | DRUG | Participants will receive IV pemetrexed Q3W until disease progression or unacceptable toxicity |
| Carboplatin | DRUG | Participants will receive IV carboplatin Q3W for four 21-day cycles |
Inclusion Criteria: * Metastatic or locally advanced unresectable, histologically documented triple-negative breast cancer (TNBC) (absence of HER2-over-expression, ER, and PgR expression by local assessment) * HER2-low-status * Measurable disease per Response Evaluation Criteria in Solid Tumors (RE...
Top 20 of 92 competitors
Tobemstomig is an investigational small molecule being studied for the treatment of breast cancer, non-small cell lung cancer, and renal cell carcinoma. It is currently in Phase 2 clinical development for these oncology indications.
Tobemstomig is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug in multiple cancer types.
Tobemstomig is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing or completed to assess its safety and efficacy in various cancers.
Tobemstomig is being studied in three Phase 2 trials. NCT05775289 evaluates it with chemotherapy in non-small cell lung cancer. NCT05805501 tests it in combination with axitinib for renal cell carcinoma. NCT05852691 studies it with nab-paclitaxel in triple-negative breast cancer.
Yes, Tobemstomig is being studied in breast cancer. A Phase 2 trial, NCT05852691, is evaluating Tobemstomig plus nab-paclitaxel compared with pembrolizumab plus nab-paclitaxel in participants with previously untreated, PD-L1-positive, locally advanced unresectable or metastatic triple-negative breast cancer.
Yes, Tobemstomig is being studied in non-small cell lung cancer. A Phase 2 trial, NCT05775289, compares Tobemstomig plus platinum-based chemotherapy with pembrolizumab plus platinum-based chemotherapy in participants with previously untreated non-small cell lung cancer.